This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Small-Cap ETF (DWAS) Hits New 52-Week High
by Sweta Killa
This small-cap ETF hits a new 52-week high. Are more gains in store for this ETF?
3 mREIT Stocks to Buy Amid Vaccine Hopes & Thanksgiving Cheer
by Devyani Chamria
The overall optimism in the market, thanks to the positive news on the vaccine front and strong rebound in the economy creates a favorable backdrop for mortgage REITs like AGNC, NLY, and RC.
Vaccine News Propels Market Higher: 5 Potential Gainers
by Zacks Equity Research
Promising vaccine news aided the market in moving higher with further economic recovery in sight, making it a good time to invest in fundamentally sound names like EnPro (NPO) and APi Group (APG).
Thanksgiving Brings Strong Seasonal Market Trends: 5 Picks
by Tirthankar Chakraborty
Traditionally, the stock market tends to perform well from the Thanksgiving week till the end of the year. This calls for investing in growth stocks like General Motors (GM) & Malibu Boats (MBUU).
ETFs to Play as Vaccine News Looks to Outdo Virus Fear
by Sanghamitra Saha
After almost a year-long wait, the month of November started delivering sweet surprises to investors in the form of back-to-back vaccine news.
Spread of Top-Ranked Value ETFs to Bet on Vaccine Optimism
by Sweta Killa
The potential arrival of a coronavirus vaccine will end the pandemic crisis, keeping the economy recovery intact, and will boost consumer spending and in turn lift value stocks.
How Does AstraZeneca's COVID-19 Vaccine Data Compare to Others'?
by Kinjel Shah
Interim data from late-stage studies on AstraZeneca (AZN) COVID-19 vaccine shows that the candidate was, on an average, about 70% effective in preventing COVID-19.
3 Coronavirus Vaccine Makers Near Finish Line in November
by Zacks Equity Research
Positive developments related to coronavirus vaccine candidates have supported stock markets in November. Three leading coronavirus vaccine candidates achieve encouraging efficacy rate.
Stock Market News for Nov 24, 2020
by Zacks Equity Research
Benchmarks closed higher on Monday after AstraZeneca and The University of Oxford said its coronavirus vaccine was up to 90% effective in trail.
5 Top-Ranked Tech Stocks to Buy Ahead of Thanksgiving
by Aniruddha Ganguly
Here we pick five technology stocks- GNRC, MTSI, SSTK, BCOV, APPS - that are well-positioned to grow on solid prospects.
Cyclical Stocks Pop on Vaccine Progress: 5 Solid Buys
by Tirthankar Chakraborty
Positive news on the COVID-19 vaccine front revitalized the U.S. economy and vis-a-vis cyclical stocks like General Motors (GM), Delta Apparel (DLA) and Deere (DE).
AstraZeneca's (AZN) sBLA for New Imfinzi Dosage Gets Approval
by Zacks Equity Research
AstraZeneca's (AZN) Imfizni is now available in monthly, fixed-dose regimen as alternative to twice-monthly, weight-based regimen for all three approved indications.
Markets Up on Sunny Holiday Outlook
by Mark Vickery
The NRF announced it expects U.S. holiday shopping season to grow 5.2% year over year, based on pent-up demand and higher U.S. savings rates during the pandemic.
AstraZeneca-Oxford Vaccine at 70% Efficacy
by Mark Vickery
One very positive piece of news from the AZN-Oxford study is that the doses may be refrigerated at normal cooler temperatures.
Stock Market News for Nov 20, 2020
by Zacks Equity Research
U.S. stock markets closed higher on Thursday on hopes of restarting of Congressional negotiations for a fresh tranche of fiscal stimulus.
5 Top Stocks to Buy Amid Potential Economic Recovery
by Zacks Equity Research
With the U.S. economy showing steady signs of a recovery and promising vaccine trials, it will be prudent to invest in fundamentally sound stocks like Crocs (CROX) and FedEx (FDX).
VBI Vaccines' (VBIV) Early Data on HBV Candidate Positive
by Zacks Equity Research
VBI Vaccines' (VBIV) early-stage hepatitis B virus immunotherapeutic candidate, VBI-2601, achieves promising immune response in patients on interim analysis.
Pfizer/BioNTech COVID-19 Vaccine Shows Final Efficacy of 95%
by Zacks Equity Research
Pfizer (PFE) and BioNTech's (BNTX) COVID-19 vaccine candidate proves to be 95% effective in final analysis.
Major Indices Fall Despite Positive Coronavirus Vaccine Data
by Indrajit Bandyopadhyay
Stock market declines as Pfizer (PFE) /BioNtech's (BNTX) vaccine candidate, with efficacy rate of 95%, gets overshadowed by fresh coronavirus cases and no sign of new fiscal stimulus.
The Zacks Analyst Blog Highlights: Walmart, AstraZeneca, HSBC Holdings, Exxon Mobil and Altria Group
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Walmart, AstraZeneca, HSBC Holdings, Exxon Mobil and Altria Group
What Awaits Pharma Giants in Last Lap of COVID-19 Vaccine Race?
by Ritujay Ghosh
Pfizer, Inc. (PFE), BioNTech SE (BNTX), Eli Lilly and Company (LLY), AstraZeneca plc (AZN), Moderna, Inc. (MRNA) and Gilead Sciences, Inc. (GILD) are leading the race to come up with a vaccine for coronavirus.
Moderna (MRNA) COVID-19 Vaccine MAA Under Rolling Review in EU
by Zacks Equity Research
Moderna (MRNA) announces start of rolling review of its regulatory application, seeking marketing authorization for its coronavirus vaccine candidate.
Top Analyst Reports for Walmart, AstraZeneca & HSBC
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Walmart (WMT), AstraZeneca (AZN) and HSBC Holdings (HSBC).
Moderna's (MRNA) Coronavirus Vaccine Progress Hurts Pfizer
by Zacks Equity Research
Moderna's (MRNA) coronavirus vaccine candidate seems to be more effective and its logistics less onerous than Pfizer and BioNTech's candidate.
Pfizer (PFE), BioNTech Fall After Moderna COVID-19 Vaccine Data
by Zacks Equity Research
Pfizer (PFE) and BioNTech's (BNTX) stocks decline after Moderna COVID-19 vaccine candidate proves 94.5% effective and can be stored at standard refrigerator temperature.